Connors et al., 1962 - Google Patents
Reduction of the toxicity of “radiomimetic” alkylating agents in rats by thiol pretreatmentConnors et al., 1962
- Document ID
- 3735013022225143226
- Author
- Connors T
- Elson L
- Publication year
- Publication venue
- Biochemical Pharmacology
External Links
Snippet
A number of thiols have been tested for their ability to protect rats against lethal doses of Merophan, an aromatic nitrogen mustard; and other biological alkylating agents. Cysteine, thiourea, AET and a thiazolidine have been shown to reduce the toxicity of the more …
- 231100000419 toxicity 0 title abstract description 38
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Connors et al. | Reduction of the toxicity of “radiomimetic” alkylating agents in rats by thiol pretreatment | |
US20090291935A1 (en) | X-nitro compounds, pharmaceutical compositions thereof and uses thereof | |
WO1986006962A1 (en) | Absorption enhancing agents | |
WO2001012169A3 (en) | Method of cancer treatment | |
CZ382799A3 (en) | Use of zinc hyaluronate against peptic ulcers | |
US4594238A (en) | Inhibition of undesired effect of platinum compounds | |
EP0651647B1 (en) | Glutathione as chemoprotective agent | |
Hobbiger et al. | Protection by Oximes of bis-Pyridinium Ions against Lethal Di iso propyl Phosphonofluoridate Poisoning | |
GR3025207T3 (en) | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | |
US4581224A (en) | Inhibition of undesired effect of platinum compounds | |
NZ228267A (en) | Anticancer formulation of a platinum-containing complex and loperamide | |
EP0192660B1 (en) | Absorption enhancing agents | |
Purpura et al. | Adjunctive treatment of murine neuroblastoma with 6-hydroxydopamine and Tempol | |
EP0434470B1 (en) | Protection against chemically-induced kidney damage by methimazole | |
US6077838A (en) | Method of treating hangover | |
US6143796A (en) | Method for reducing development of free radical induced malignancies | |
US6034126A (en) | Method for treating glycol poisoning | |
IL36587A (en) | Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions | |
US6172119B1 (en) | Method of treating acute renal failure | |
Foster et al. | Metronidazole (Flagyl) in cancer radiotherapy | |
US5087441A (en) | Protection against chemically-induced kidney damage by methimazole | |
Melville et al. | Toxic and protective effects of AET upon normal and irradiated female rats | |
US3345415A (en) | N-n-alkylaminoethanethiols | |
US6468993B1 (en) | Method for reducing development of osteoporosis | |
US6525037B1 (en) | Method of treating atherosclerosis and complications resulting therefrom |